HUP0400651A2 - Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0400651A2
HUP0400651A2 HU0400651A HUP0400651A HUP0400651A2 HU P0400651 A2 HUP0400651 A2 HU P0400651A2 HU 0400651 A HU0400651 A HU 0400651A HU P0400651 A HUP0400651 A HU P0400651A HU P0400651 A2 HUP0400651 A2 HU P0400651A2
Authority
HU
Hungary
Prior art keywords
factor
serine protease
pharmaceutical compositions
compositions containing
acid derivatives
Prior art date
Application number
HU0400651A
Other languages
English (en)
Inventor
Gregory S. Bisacchi
Daniel L. Cheney
Yan Shi
William A. Slusarchyk
James C. Sutton
Uwe D. Treuner
Shung C. Wu
Guohua Zhao
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HUP0400651A2 publication Critical patent/HUP0400651A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

A találmány tárgyát az általános képletű vegyületek - ahol Bfenilgyűrű vagy piridilgyűrű, W előnyösen -C(=O)NR4R5 általánosképletű csoport, L távtartó csoport, X2 nitrogén- vagy szénatom, Zadott esetben szubsztituált monociklusos vagy biciklusos csoport, ésR1, R2, R3, R4, R5 és R6 a szerves kémia területén szokásos, adottesetben összetett, a leírásban részletesen meghatározott szubsztituens- és ezeket artalmazó, szerin proteáz, pontosabban a VIIa. faktor,IXa. faktor, Xa. faktor és/vagy XIa. faktor inhibitoraikéntalkalmazható gyógyszerkészítmények és előállításuk képezik. Ó
HU0400651A 2000-11-07 2001-11-07 Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények HUP0400651A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24639200P 2000-11-07 2000-11-07
PCT/US2001/046884 WO2002042273A2 (en) 2000-11-07 2001-11-07 Acid derivatives useful as serine protease inhibitors

Publications (1)

Publication Number Publication Date
HUP0400651A2 true HUP0400651A2 (hu) 2004-06-28

Family

ID=22930465

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400651A HUP0400651A2 (hu) 2000-11-07 2001-11-07 Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények

Country Status (7)

Country Link
US (1) US6642252B2 (hu)
EP (1) EP1332131A2 (hu)
JP (1) JP2004514669A (hu)
AU (1) AU2002227269A1 (hu)
CA (1) CA2428191A1 (hu)
HU (1) HUP0400651A2 (hu)
WO (1) WO2002042273A2 (hu)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
AR024158A1 (es) 1999-06-01 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
ATE285821T1 (de) 1999-10-08 2005-01-15 Affinium Pharm Inc Fab i inhibitoren
US6906192B2 (en) 2000-11-07 2005-06-14 Bristol Myers Squibb Company Processes for the preparation of acid derivatives useful as serine protease inhibitors
CA2432644C (en) * 2000-12-25 2013-07-23 Fumitoshi Asai Pharmaceutical composition comprising aspirintm and cs-747
WO2003088897A2 (en) 2001-04-06 2003-10-30 Affinium Pharmaceuticals, Inc. Fab i inhibitors
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
JPWO2002098840A1 (ja) 2001-06-04 2004-09-16 エーザイ株式会社 カルボン酸誘導体及びその塩もしくはそのエステルからなる医薬
KR101089438B1 (ko) * 2001-06-29 2011-12-07 가부시키가이샤 시세이도 복합분체 및 이를 배합시킨 피부외용제
ES2336094T3 (es) 2002-03-29 2010-04-08 Novartis Vaccines And Diagnostics, Inc. Benzazoles sustituidos y uso de los mismos como inhibidores de quinasa raf.
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
WO2004072102A2 (en) * 2003-02-11 2004-08-26 Bristol-Myers Squibb Company Benzene acetamide compounds useful as serine protease inhibitors
WO2004072101A2 (en) * 2003-02-11 2004-08-26 Bristol-Myers Squibb Company Phenylglycine derivatives useful as serine protease inhibitors
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
AR045979A1 (es) * 2003-04-28 2005-11-23 Astrazeneca Ab Amidas heterociclicas
EP1631556A1 (en) * 2003-05-16 2006-03-08 Novartis AG Pharmaceutical composition comprising valsartan
EP1626966A1 (en) * 2003-05-20 2006-02-22 Genentech, Inc. Benzofuran inhibitors of factor viia
CA2525854C (en) * 2003-05-20 2009-12-15 Genentech, Inc. Acylsulfamide inhibitors of factor viia
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
AU2004265189B2 (en) 2003-08-15 2010-03-04 Banyu Pharmaceutical Co., Ltd. Imidazopyridine derivatives
NZ545864A (en) 2003-09-22 2009-12-24 S Bio Pte Ltd Benzimidazole derivates: preparation and pharmaceutical applications
DE602004021838D1 (de) 2003-10-16 2009-08-13 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
JPWO2005108399A1 (ja) 2004-05-10 2008-03-21 萬有製薬株式会社 イミダゾピリジン化合物
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7576098B2 (en) * 2004-12-08 2009-08-18 Bristol-Myers Squibb Company Heterocyclic compounds as inhibitors of factor VIIa
JP4988591B2 (ja) * 2004-12-17 2012-08-01 イーライ リリー アンド カンパニー 新規なｍｃｈ受容体アンタゴニスト
DK1848430T3 (da) 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
ES2349428T3 (es) * 2005-01-10 2011-01-03 Bristol-Myers Squibb Company Derivados de fenilglicinamida útiles como anticoagulantes.
EP1856053A1 (en) 2005-01-14 2007-11-21 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
EP1846411A4 (en) 2005-01-25 2010-08-04 Glaxo Group Ltd ANTIBACTERIAL ACTIVE SUBSTANCES
MX369262B (es) 2005-02-16 2019-11-04 Anacor Pharmaceuticals Inc Moleculas pequeñas que contienen boro.
WO2007002313A2 (en) * 2005-06-24 2007-01-04 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
WO2007070818A1 (en) * 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
AR058380A1 (es) * 2005-12-23 2008-01-30 Bristol Myers Squibb Co Inhibidores del factor viia macrociclicos utiles como anticoagulantes
CN105949230A (zh) 2005-12-30 2016-09-21 安纳考尔医药公司 含硼的小分子
CN101500993A (zh) 2006-06-08 2009-08-05 百时美施贵宝公司 作为凝血因子Ⅶa抑制剂用作抗凝血药的2-氨基羰基苯基氨基-2-苯基乙酰胺
US8318720B2 (en) 2006-07-20 2012-11-27 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as Fab I inhibitors
WO2008031509A1 (de) 2006-09-13 2008-03-20 Sanofi-Aventis Isoserinderivate als inhibitoren des koagulationsfaktors ixa
BRPI0716778A2 (pt) 2006-09-13 2014-04-22 Sanofi Aventis Derivados de tartarato para uso como inibidores do fator de coagulação ixa
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
JP2010513562A (ja) * 2006-12-20 2010-04-30 ブリストル−マイヤーズ スクイブ カンパニー 抗凝血剤として有用な二環状ラクタム第ｖｉｉａ因子阻害剤
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
CA2850022C (en) 2011-09-27 2018-05-01 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
HUE043836T2 (hu) 2012-06-19 2019-09-30 Debiopharm Int Sa (E)-N-metil-N-((3-metilbenzofuran-2-il)metil)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamid prodrug származékai
KR101942752B1 (ko) * 2012-11-05 2019-01-28 주식회사 엘지화학 Ｇｐｒ120 효능제로서의 티오아릴 유도체
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
ES2659045T3 (es) 2013-10-30 2018-03-13 Bayer Pharma Aktiengesellschaft Derivados de oxopiridina sustituidos
WO2015123093A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Factor xia inhibitors
US9676723B2 (en) 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
EP3134408B1 (en) 2014-04-22 2020-08-12 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2016015593A1 (en) 2014-07-28 2016-02-04 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2016029216A2 (en) * 2014-08-22 2016-02-25 Biocryst Pharmaceuticals, Inc. Method for producing amidine derivatives
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2016046156A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2016046158A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CA2990165C (en) 2015-02-02 2023-12-12 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0]hydroxamic acids as hdac inhibitors
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
KR20180073602A (ko) 2015-10-29 2018-07-02 머크 샤프 앤드 돔 코포레이션 인자 XIa 억제제
WO2017074833A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
MY189221A (en) 2016-02-26 2022-01-31 Debiopharm Int Sa Medicament for treatment of diabetic foot infections
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
US10143681B2 (en) 2016-08-22 2018-12-04 Merck Sharp & Dohme Corp. Factor XIa inhibitors
MA49566A (fr) 2017-07-11 2020-05-20 Vertex Pharma Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
CN109879808B (zh) * 2019-03-05 2020-10-16 北京工业大学 一种含五元唑类杂环基查尔酮类衍生物及制备方法和医药用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5137818B2 (hu) 1972-09-01 1976-10-18
US3995045A (en) * 1975-09-25 1976-11-30 E. R. Squibb & Sons, Inc. 2'-[(3,6-Dihydro-phenyl-1(2H)pyridinyl)alkylaminocarbonyl][1,1'-biphenyl]-2-carboxylic acids
GB2056968A (en) 1979-08-21 1981-03-25 Fujisawa Pharmaceutical Co Piperazine derivative, processes for the preparation thereof and pharmaceutical composition comprising the same
US4786755A (en) 1985-06-03 1988-11-22 Warner-Lambert Company Diphenic acid monoamides
JPH0623151B2 (ja) 1989-06-02 1994-03-30 田辺製薬株式会社 ビフェニル誘導体、その製法及びその合成中間体
US5612341A (en) 1995-06-07 1997-03-18 Biotech Research Laboratories Brominated hexahydroxybiphenyl derivatives
WO1997031910A1 (en) 1996-02-28 1997-09-04 Merck & Co., Inc. Fibrinogen receptor antagonists
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
BR9810151A (pt) 1997-06-19 2000-08-08 Du Pont Pharm Co Composto, composição farmacêutica e método para tratamento ou prevenção de uma desordem tromoboembólica
AU2300699A (en) * 1998-02-17 1999-08-30 Ono Pharmaceutical Co. Ltd. Amidino derivatives and drugs containing the same as the active ingredient
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
TR200200795T2 (tr) 1999-09-25 2002-07-22 Smithkline Beecham P. L. C. 5-HT1B antagonistleri olarak piperazin türevleri
US20030232789A1 (en) 1999-12-15 2003-12-18 Allen Darin Arthur Salicylamides as serine protease and factor xa inhibitors
DE10014645A1 (de) 2000-03-24 2001-09-27 Merck Patent Gmbh Substituierte Biphenylderivate
RU2003104017A (ru) 2000-07-12 2004-08-20 Акцо Нобель Н.В. (NL) Ингибиторы тромбина, содержащие аминоизохинолиновую группу
DE10046272A1 (de) 2000-09-19 2002-03-28 Merck Patent Gmbh Aminoheterocyclen (Faktor Xa Inhibitoren 14)
AU2002213393B2 (en) * 2000-10-20 2007-02-15 Biocryst Pharmaceuticals, Inc. Biaryl compounds as serine protease inhibitors

Also Published As

Publication number Publication date
US6642252B2 (en) 2003-11-04
EP1332131A2 (en) 2003-08-06
AU2002227269A1 (en) 2002-06-03
WO2002042273A3 (en) 2002-08-29
JP2004514669A (ja) 2004-05-20
US20030166685A1 (en) 2003-09-04
CA2428191A1 (en) 2002-05-30
WO2002042273A2 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
HUP0400651A2 (hu) Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
HUP0402529A2 (hu) Xa faktor és más, a koagulációs kaszkádban részt vevő szerin-proteázok inhibitorai, eljárás előállításukra és ezeket hatóanyagként tartalmazó gyógyszerkészítmények
GEP20074098B (en) Lactam-containing compounds and derivatives thereof as factor xa inhibitors
HUP0100669A2 (hu) Szerin proteázokat gátló peptidszármazékok és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
CY1113487T1 (el) Νεα παραγωγα μανδελικου οξεος και η χρηση τους ως αναστολεις θροβινης
NO20062644L (no) DPP-IV inhibitorer
CY1107149T1 (el) Νεα παραγωγα αμιδινοβενζυλαμινης και χρηση τους ως αναστολεων θρομβινης
EA200500017A1 (ru) Новые соединения
BG106013A (en) New compounds and compositions as protease inhibitors
EA200100675A1 (ru) Ингибиторы протеазы
DE60022508D1 (de) Inhibitoren von serin proteasen
NO20020217L (no) Nitrogenholdige heterobisykler som faktor Xa-inhibitorer
MX2007005408A (es) Compuestos de aminoquinazolinas.
HUP0300832A2 (hu) Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
PE20061153A1 (es) Compuestos heterociclicos como inhibidores del factor viia
HUP0301391A2 (hu) Piperazin- és piperidinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0102723A2 (hu) Új difenilkarbamid-származékok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények
ZA200409379B (en) Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
TW223630B (en) Retroviral protease inhibitors
WO2002037937A3 (en) Acid derivatives useful as serine protease inhibitors
MXPA04009476A (es) Compuestos de (tiazol-4,2-disustituidos-5-il)amina como inhibidores de la pde7.
GEP20063896B (en) New heterocyclic oxime compound, method for production of the same and pharmaceutical composition comprising the same
MXPA05000004A (es) Derivados de triazina y oxazina como inhibidores de la metaloproteasa-13 de matriz para tratar artritis.
DK1644385T3 (da) Siliciumforbindelser og deres anvendelse